SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : Idea Of The Day -- Ignore unavailable to you. Want to Upgrade?

To: Coz who wrote (23183)2/1/1999 5:09:00 PM
From: Anthony Wong  Read Replies (1) | Respond to of 50167
 
Cosmo, thanks for the feedback. The general consensus is that Celebrex may not be more effective than older drugs; the main benefit is the improved safety. Some arthritic suffers cannot tolerate NSAIDs (stomach irritations and bleeding ulcers). It is not expected that Celebrex and other Cox-2 inhibitors would get all the market share, as obviously those who well tolerate NSAIDs would have no need to switch.

Regards.

Anthony



HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News